Screener
PTC Therapeutics PTCT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable and accrued expenses | $313,050 | $381,272 |
| Current portion of long-term debt | 286,937 | 286,631 |
| Deferred revenue | 498 | 2,040 |
| Operating lease liabilities- current | 12,078 | 12,484 |
| Finance lease liabilities- current | 6,000 | 3,000 |
| Liability for sale of future royalties- current | 305,041 | 283,000 |
| Total current liabilities | 923,604 | 968,427 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's deferred revenue?
- PTC Therapeutics (PTCT) reported deferred revenue of $498K in Q1 2026.
- How has PTC Therapeutics's deferred revenue changed year-over-year?
- PTC Therapeutics's deferred revenue decreased by 96.1% year-over-year, from $12.83M to $498K.
- What is the long-term trend for PTC Therapeutics's deferred revenue?
- Over 4 years (2020 to 2025), PTC Therapeutics's deferred revenue has grown at a -16.3% compound annual growth rate (CAGR), from $4.15M to $2.04M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about PTC Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude